Ignite Creation Date:
2025-12-25 @ 3:23 AM
Ignite Modification Date:
2025-12-26 @ 2:02 AM
Study NCT ID:
NCT03607305
Status:
COMPLETED
Last Update Posted:
2018-07-31
First Post:
2018-07-23
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Impact of Biliopancreatic Limb Lenght on Long-term Weight Loss After Roux-en-Y Gastric Bypass
Sponsor:
Hospital General Universitario Elche
Organization:
Study Overview
Official Title:
Impact of Biliopancreatic Limb Lenght on Long-term Weight Loss After Roux-en-Y Gastric
Status:
COMPLETED
Status Verified Date:
2018-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients were randomly assigned into 2 groups: those patients undergoing RYGB with a BPL of 70cm and those ones undergoing RYGB with a BPL of 120 cm.
Excess BMI loss 5 years after surgery was investigated
Excess BMI loss 5 years after surgery was investigated
Detailed Description:
Patients were randomly assigned into 2 groups: those patients undergoing Roux-en-Y gastric bypass with a biliopancreatic limb of 70cm and those ones undergoing Roux-en-Y gastric bypass with a biliopancreatic limb of 120 cm. Alimentary limb was constant in both groups (150cm).
Excess BMI loss 5 years after surgery was investigated
Excess BMI loss 5 years after surgery was investigated
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: